The clinical significance of p53 aberrations in human tumours

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

p53 aberrations are the most common genetic alteration found in human tumours and this review summarizes the current understanding of the clinical significance of p53 abnormalities. Immunohistochemical and molecular techniques can demonstrate alterations at the protein and gene level, respectively, but with a significant discordance between the findings of either technique. The tumours evaluated in this review include cancers of the breast, lung, gastrointestinal tract, genitourinary tract, and others. In most cases, only data on p53 protein are available and in each of these tumour types discrepant conclusions on the clinical value of p53 abnormalities as prognostic indicators have been reached. The role of p53 in the context of anticancer adjuvant therapy has also been analysed. Experimental data suggest that p53 affects the apoptotic response to anticancer agents, but this has not yet been proven in a clinical series where this demonstration and its effect on therapy could represent one of the most important endpoints in p53 clinical research. The use of standardized techniques to evaluate p53 gene mutation and protein accumulation within controlled clinical series of patients entering prospective trials is essential to answer the many remaining questions on the clinical significance of p53 aberrations.

Original languageEnglish
Pages (from-to)229-241
Number of pages13
JournalVirchows Archiv
Volume427
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Neoplasms
Proteins
p53 Genes
Antineoplastic Agents
Gastrointestinal Tract
Lung Neoplasms
Breast Neoplasms
Therapeutics
Research
Mutation Accumulation

Keywords

  • Human tumours
  • Immunohistochemistry
  • p53

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The clinical significance of p53 aberrations in human tumours. / Bosari, S.; Viale, G.

In: Virchows Archiv, Vol. 427, No. 3, 2004, p. 229-241.

Research output: Contribution to journalArticle

@article{130aa46afd93497d958f4b3f817cbfe0,
title = "The clinical significance of p53 aberrations in human tumours",
abstract = "p53 aberrations are the most common genetic alteration found in human tumours and this review summarizes the current understanding of the clinical significance of p53 abnormalities. Immunohistochemical and molecular techniques can demonstrate alterations at the protein and gene level, respectively, but with a significant discordance between the findings of either technique. The tumours evaluated in this review include cancers of the breast, lung, gastrointestinal tract, genitourinary tract, and others. In most cases, only data on p53 protein are available and in each of these tumour types discrepant conclusions on the clinical value of p53 abnormalities as prognostic indicators have been reached. The role of p53 in the context of anticancer adjuvant therapy has also been analysed. Experimental data suggest that p53 affects the apoptotic response to anticancer agents, but this has not yet been proven in a clinical series where this demonstration and its effect on therapy could represent one of the most important endpoints in p53 clinical research. The use of standardized techniques to evaluate p53 gene mutation and protein accumulation within controlled clinical series of patients entering prospective trials is essential to answer the many remaining questions on the clinical significance of p53 aberrations.",
keywords = "Human tumours, Immunohistochemistry, p53",
author = "S. Bosari and G. Viale",
year = "2004",
doi = "10.1007/BF00203389",
language = "English",
volume = "427",
pages = "229--241",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The clinical significance of p53 aberrations in human tumours

AU - Bosari, S.

AU - Viale, G.

PY - 2004

Y1 - 2004

N2 - p53 aberrations are the most common genetic alteration found in human tumours and this review summarizes the current understanding of the clinical significance of p53 abnormalities. Immunohistochemical and molecular techniques can demonstrate alterations at the protein and gene level, respectively, but with a significant discordance between the findings of either technique. The tumours evaluated in this review include cancers of the breast, lung, gastrointestinal tract, genitourinary tract, and others. In most cases, only data on p53 protein are available and in each of these tumour types discrepant conclusions on the clinical value of p53 abnormalities as prognostic indicators have been reached. The role of p53 in the context of anticancer adjuvant therapy has also been analysed. Experimental data suggest that p53 affects the apoptotic response to anticancer agents, but this has not yet been proven in a clinical series where this demonstration and its effect on therapy could represent one of the most important endpoints in p53 clinical research. The use of standardized techniques to evaluate p53 gene mutation and protein accumulation within controlled clinical series of patients entering prospective trials is essential to answer the many remaining questions on the clinical significance of p53 aberrations.

AB - p53 aberrations are the most common genetic alteration found in human tumours and this review summarizes the current understanding of the clinical significance of p53 abnormalities. Immunohistochemical and molecular techniques can demonstrate alterations at the protein and gene level, respectively, but with a significant discordance between the findings of either technique. The tumours evaluated in this review include cancers of the breast, lung, gastrointestinal tract, genitourinary tract, and others. In most cases, only data on p53 protein are available and in each of these tumour types discrepant conclusions on the clinical value of p53 abnormalities as prognostic indicators have been reached. The role of p53 in the context of anticancer adjuvant therapy has also been analysed. Experimental data suggest that p53 affects the apoptotic response to anticancer agents, but this has not yet been proven in a clinical series where this demonstration and its effect on therapy could represent one of the most important endpoints in p53 clinical research. The use of standardized techniques to evaluate p53 gene mutation and protein accumulation within controlled clinical series of patients entering prospective trials is essential to answer the many remaining questions on the clinical significance of p53 aberrations.

KW - Human tumours

KW - Immunohistochemistry

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0028841050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028841050&partnerID=8YFLogxK

U2 - 10.1007/BF00203389

DO - 10.1007/BF00203389

M3 - Article

VL - 427

SP - 229

EP - 241

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 3

ER -